Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
2,600
Views
9
CrossRef citations to date
0
Altmetric
Author's View

No time to die: the consensus immunoscore for predicting survival and response to chemotherapy of locally advanced colon cancer patients in a multicenter international study

Paolo A. Asciertoa Melanoma, Cancer Immunotherapy and Innovative Therapies Unit, Istituto Nazionale Tumori IRCCS Fondazione “G. Pascale”, Napoli, ItalyORCID Iconhttps://orcid.org/0000-0002-8322-475XView further author information
ORCID Icon,
Francesco M. Marincolab Refuge Biotechnologies, Menlo Park, CA, USAView further author information
,
Bernard A. Foxc Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR, USA;d Laboratory of Molecular and Tumor Immunology, Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, Portland, OR, USAView further author information
&
Jérôme Galone Laboratory of Integrative Cancer Immunology, INSERM, Paris, France;f Equipe Labellisée Ligue Contre le Cancer, Paris, France;g Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9635-1339View further author information
ORCID Icon
Article: 1826132 | Received 14 Sep 2020, Accepted 16 Sep 2020, Published online: 13 Oct 2020

Figures & data

Figure 1. Clinical utility of the Immunoscore. (a) Immunoscore and intratumoral T-cell repertoire remain stable with age. (b) Relative contribution of each risk parameter to survival risk for overall survival in Stage III CC using the x2 proportion test for clinical parameters and Immunoscore. (c) Immunoscore is a powerful prognosis marker and a predictive marker of response to chemotherapy for stage III colon cancer patients

Figure 1. Clinical utility of the Immunoscore. (a) Immunoscore and intratumoral T-cell repertoire remain stable with age. (b) Relative contribution of each risk parameter to survival risk for overall survival in Stage III CC using the x2 proportion test for clinical parameters and Immunoscore. (c) Immunoscore is a powerful prognosis marker and a predictive marker of response to chemotherapy for stage III colon cancer patients

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.